NeoGenomics Inc (NASDAQ:NEO) on Tuesday posted fourth-quarter results that topped Wall Street estimates, though shares declined sharply in early trading as investors weighed the company’s growth outlook.
The cancer diagnostics specialist saw its stock fall 5.27% in pre-market activity following the earnings release.
Adjusted earnings for the quarter came in at $0.06 per share, exceeding the analyst consensus of $0.04.
Revenue reached $190.17 million, ahead of the $188.14 million expected by analysts and up 11% from the same quarter last year.
Growth was fueled by higher clinical testing volumes, with next-generation sequencing (NGS) increasing 23% in the fourth quarter and 22% for the full year. Average revenue per clinical test rose 5% to $488, or 7% excluding contributions from recently acquired Pathline tests.
“We ended 2025 on a strong note, delivering double-digit revenue growth in the fourth quarter on the strength of our clinical volumes and ongoing mix shift toward higher value tests,” said Tony Zook, CEO of NeoGenomics.
For full-year 2025, consolidated revenue climbed 10% to $727 million. However, the company reported a net loss of $108 million, widening from $79 million in 2024. Adjusted EBITDA increased 9% year over year to $43 million.
Looking ahead, NeoGenomics projected 2026 revenue in the range of $793 million to $801 million, broadly aligned with the $796.7 million consensus estimate. The company expects a net loss between $63 million and $50 million and adjusted EBITDA of $55 million to $57 million.
Management also highlighted the planned clinical launch of its RaDaR ST MRD assay, targeting the more than $20 billion molecular residual disease monitoring market, though it anticipates only limited revenue contribution from the product in 2026.
NeoGenomics ended the quarter with $160 million in cash and cash equivalents.